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This study tested the hypothesis that enhancement of blood cardioplegia with the 
nitric oxide donor agent SPM-5185 inhibits postischemic left ventricular and 
coronary endothelial dysfunction. Eighteen anesthetized dogs supported by total 
vented bypass were subjected to 30 minutes of normothermic schemia followed by 
4 ° C multidose blood cardioplegia. Hearts received either standard blood cardiople- 
gia (vehicle group; n = 6), blood cardioplegia with 1 pmol/L SPM-5185 (low-dose 
group; n = 6) ,  or 10/.tmol/L SPM.5185 (high-dose group; n = 6). After 60 minutes 
of cardioplegic arrest, the heart was reperfused for a total of 60 minutes, first in the 
beating empty state for 30 minutes and then after discontinuation of bypass for 30 
minutes. Baseline and postischemic left ventricular function was assessed by the 
slope of the end-systolic pressure-volume (impedance catheter) relation. Postisch- 
emic end-systolic pressure-volume relation was depressed by 53.7% of preischemic 
values in the vehicle group (from 8.2  - 1.0 to 3.8 -+ 0.3 mm Hg/ml) and by 33.7% 
(from 9.2  - 1.1 to 6.1 _ 0.5 mm Hg/ml) in the low-dose group. In contrast, there was 
complete postischemic functional recovery in the high-dose group (from 7.6 - 1.1 to 
7.2 _-+ 1.2 mm Hg/ml). In coronary arteries isolated from these hearts, endothelium- 
dependent maximal relaxation to acetylcholine was impaired by 27% in the vehicle 
group and by 18% in the low-dose group, whereas the high-dose group showed 
complete ndothelium-dependent r laxation. Myeloperoxidase activity, an index of 
neutrophil accumulation in postischemic myocardium, was elevated in the vehicle 
and low-dose groups (3.36 _+ 0.58 and 2.56 - 0.68 U/100 mg tissue) but was 
significantly reduced in the high-dose group to 1.27 _+ 0.45 U/100 mg tissue. We 
conclude that inclusion of 10 /.tmol/L nitric oxide donor SPM-5185 in blood 
cardioplegia improves postischemic ventricular performance and endothelial func- 
tion in ischemically injured hearts, possibly via inhibition of neutrophil-mediated 
damage. (J THORAC CARDIOVASC SURG 1995;109:1146-54) 
Katsuhiko Nakanishi, MD, Zhi-Qing Zhao, PhD, J. Vinten-Johansen, PhD, 
Dudley A. Hudspeth, MD, D. Scott McGee, BS, and John W. Hammon, Jr., MD, 
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T here is increasing evidence that myocardial isch- emia and reperfusion cause coronary endothelial 
damage, which results in a decreased release or 
production of endothelium-derived relaxing factor 
from the vascular endothelium. 1-4 Endothelium- 
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derived relaxing factor is identical to nitric oxide 
(NO) 5 or a nitroso-containing compound and has 
various physiologic properties including vasodila- 
tion, inhibition of platelet aggregation 6 and neutro- 
phil adhesion, 7 and biradical quenching of super- 
oxide anions, s' 9 Because neutrophil activation and 
oxygen radicals have been implicated as major mech- 
anisms of myocardial ischemia-reperfusion injury, 1° 
attenuation of NO release caused by endothelial dam- 
age after reperfusion may exacerbate he extent of post- 
ischemic injury and may be a critical mechanism in the 
dynamics of myocardial ischemia-repeffusion injury. 4 
In the development of myoprotective strategies 
with the use of cardioplegic solutions, attention has 
been primarily focused on protecting myocytes from 
morphologic injury and contractile dysfunction. 
However, recent studies have demonstrated the 
extreme vulnerability of endothelial cells to post- 
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ischemic (reperfusion) injury. 4' 11 A recent study 
from our laboratory showed that neither brief nor- 
mothermic global ischemia nor cardioplegic arrest 
with blood cardioplegia (BCP) in the absence of 
reperfusion impaired coronary endothelial func- 
tion. 12 However, endothelial damage was mani- 
fested only after unmodified blood reperfusion after 
removal of the aortic crossclamp, with or without 
intervening cardioplegia. Cardioplegic solutions 
could be an ideal vehicle for the introduction of 
agents that target the perpetrators of endothelial 
injury during elective cardiac arrest and subsequent 
reperfusion. Replacement of lost (secondary to endo- 
thelial damage) endogenous NO with authentic NO, 13 
an exogenous NO donor, or supplementation with the 
precursor of NO (that is, L-arginine) may prevent 
endothelial damage and pathologic sequelae. 4' 14 
This study tested the hypothesis that the NO 
donor compound SPM-5185 used in blood cardio- 
plegia would attenuate ndothelial dysfunction and 
preserve postischemic left ventricular function in the 
dog subjected to normothermic schemia, multidose 
BCP, and reperfusion. 
Material and methods 
Surgical procedure. Surgical and cardiopulmonary b - 
pass procedures have been described in detail else- 
where j2, ~5 Heartworm-free adult mongrel dogs of either 
sex weighing 18.9 to 26.6 kg (average 22.1 + 1.3 kg) were 
anesthetized with intravenous sodium thiamylal (20 rag/ 
kg) followed by fentanyl citrate (350 /xg) and diazepam 
(5 mg) as needed during the experiment. After median 
sternotomy and heparinization (300 U/kg, supplemented 
every 90 minutes), the left subclavian artery was cannu- 
lated and the pericardium was incised and tented. A 
Millar MPC-500 temperature-compensating solid-state 
catheter (Millar Instruments, Houston, Tex.) was placed 
in the proximal aorta through the right internal mammary 
artery. The left ventricle was instrumented to measure 
instantaneous pressure (Millar MPC-500) and volume 
(Webster 7F octapolar catheter, Anaheim, Calif.) as de- 
scribed previously) 5 
The superior and inferior venae cavae were transatrially 
cannulated and the venous return cannulas temporarily 
posed in the right atrium to prevent obstruction of venous 
return while the circulation was intact. Three to five sets of 
preischemic left ventricular function data were acquired 
during a 12-second period of respiratory apnea by tran- 
siently occluding the superior and inferior venae cavae 
with the snares. This resulted in a gradual time-varying 
reduction in sequential pressure-volume loops from which 
systolic and diastolic functional parameters were derived 
(see following sections). 15' 16 Cardiopulmonary b pass was 
instituted with the use of a Sarns membrane oxygenator 
model 9443 (Sarns/3M, Ann Arbor, Mich.) primed with 
1.5 L hetastarch (Hespan; DuPont Pharmaceutical, Wllm- 
ington, Del.). The left and right ventricles were vented by 
direct cannulation and gravity drainage. Finally, a double- 
lumen aortic root cannula (DPL, Inc., Grand Rapids, 
Mich.) was inserted for delivery of BCP and simultaneous 
measurement of BCP infusion pressure. 
The aorta was crossclamped to initiate unmodified 
normothermic ischemia for 30 minutes, and mean aortic 
pressure was maintained at 60 to 70 mm Hg. A myocardial 
temperature probe (Shiley, Irvine, Calif.) was placed in 
the anterior and posterior walls of the left ventricle. 
Sodium bicarbonate was used to counteract acidemia nd 
maintain arterial pH between 7.35 and 7.45. 
Experimental protocol (Fig. 1). After 30 minutes of 
normothermic global ischemia, multidose hypothermic 
BCP arrest was initiated with a 4:1 ratio of BCP solution 
delivered by a Buckberg-Shiley s stem (Shiley, Inc.) and 
the cold induction technique as previously describedJ 5'16 
The dogs were randomly divided into three groups on the 
basis of the exclusion or inclusion of the cysteine-contain- 
ing NO donor compound SPM-5185 in BCP solution. In 
the vehicle group (VEH, n = 10), unmodified standard 
BCP solution was used (Table I). In another group, 
low-dose SPM-5185 (SPM-L, n = 7) was added to BCP 
solution to achieve a final concentration of 1 /xmol/L. In 
the third group, high-dose SPM-5185 (SPM-H, n = 7) was 
added to BCP solution to achieve afinal concentration f
10/xmol/L. Systemic rewarming to 37 ° C was achieved and 
the crossclamp was removed immediately after comple- 
tion of the terminal BCP infusion. 
Reperfusion. After removal of the aortic crossclamp, 
mean aortic pressure was gradually increased from 50 mm 
Hg to 80 mm Hg after electromechanical reanimation was 
observed. When ventricular fibrillation occurred, direct- 
current countershocks of 10 watt-seconds were applied. 
The heart was maintained in the total vented bypass tate 
for the initial 30 minutes of reperfusion. Systemic blood 
Ca 2÷ was corrected to baseline values, and the dog was 
weaned off bypass for an additional 30 minutes with the 
heart in the working state. After functional data were 
acquired at the end of 60 minutes of reperfusion, the heart 
was excised for the subsequent s udy of endothelial func-- 
tion by the coronary ring-organ bath techniqueJ a The 
excised hearts from each group were immediately im.- 
mersed in cold Krebs-Henseleit solution with the follow- 
ing composition (millimolars per liter): 118 NaC1, 4.7 KC1, 
1~2 KH2PO4, 1.2 MgSO4, 2.5 CaCI2, 12.5 NaHCO3, and 10 
glucose. 
The dogs were handled in compliance with the "Guide 
for the Care and Use of Laboratory Animals" published 
by the National Institutes of Health (NIH Publication No. 
85-23, revised 1985). The institutional Animal Care and 
Use Committee approved the study protocol. 
Data acquisition and analysis. Analog hemodynamic 
data were recorded on a microcomputer system (IBM-PC 
AT) by use of an analog-to-digital converter (Data Trans- 
lation, model DT2821, Marlboro, Mass.) sampling at 250 
Hz and analyzed with use of an interactive videographics 
program developed in our laboratory. 17Left ventricular 
chamber conductance was converted to volume with use 
of the Leycom Sigma 5 signal conditioner and processor 
(Oegstgeest, The Netherlands). The conductivity of blood 
was measured periodically throughout the experiment. 
Parallel conductance volume (Vp) was determined in 
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Fig. 1. Experimental protocol. Hearts placed on cardiopulmonary b pass were subjected to 30 minutes of 
normothermic global ischemia followed by 60 minutes of hypothermic cardioplegic arrest with multidose 
BCP (every 20 minutes). Thirty minutes were allowed for reperfusion in beating empty state, after which 
bypass was discontinued to convert heart to working state for another 30 minutes. Hemodynamic and left 
ventricular (LV) function data were obtained uring baseline and after 60 minutes of reperfusion. 
Table I. Composition of blood cardioplegia 
Constituent Value 
Potassium ion (KC1) 20-25 (induction, terminal infusions), 
(mmol/L) 10 (intermittent infusions) 
Calcium ion (CPD) 0.3 
(mmol/L) 
Magnesium ion (derived 0.5 
from blood) (mmol/L) 
pH (THAM buffer) 8.2 (at 4 ° C) 
Osmolality (mOsm/L) 360-380 
Hematocrit (%) 14-18 
Oxygen content 8-10 
(ml O2/100 ml) 
CPD, Citrate-phosphate-dextrose (blood); THAM, tris(hydroxymethyl)- 
aminomethane. 
triplicate at baseline and after ischemia by the bolus 
hypertonic saline technique and subtracted from the 
instantaneous total volume signal to obtain the corrected 
instantaneous absolute left ventricular blood volume. 
Calculations 
End-systolic pressure-volume relation (ESPVR). Left 
ventricular systolic performance was described by ESPVR 
derived from the instantaneous pressure-volume data as 
described previouslyJ 5' 18 VMID, the volume calculated 
when end-systolic pressure (P~) was within the physio- 
logic range (80 to 100 mm Hg), was used as a descriptor of 
18 the position of the ESPVR. The value of P~s chosen to 
derive VMm was consistent within each experiment. 
Preload recruitable stroke work (PRSW). Left ventricular 
stroke work (SW) was calculated by point-by-point inte- 
gration of left ventricular pressure and volume (SW = f P 
• dV), where P is left ventricular instantaneous pressure 
and dV is rate of volume changesJ 9 Regression analysis was 
performed to fit stroke work for each loop to its correspond- 
hag end-diastolic volume (Veal) using the equation 
SW = Msw (red -- Vsw, o) 
where Msw is the slope of the linear SW - Vea relation 
and Vsw,o is the volume intercept where SW = 0 mm Hg 
• mm. 
End-diastolic pressure-volume relation. The exponential 
end-diastolic pressure-volume was used to determine the 
characteristics of left ventricular chamber stiffness (the 
inverse of compliance) as previously described. 15 The 
exponential/3 coefficient is the unitless modulus of cham- 
ber stiffness used to describe the degree of curvature of 
the end-diastolic pressure-volume relation. 
In vitro coronary ring studies. Both the left anterior 
descending coronary artery and the left circumflex coro- 
nary artery were carefully dissected from the heart and 
placed in cold Krebs-Henseleit solution and cleaned of 
adipose and connective tissue. The isolated left anterior 
descending and circumflex artery segments were each cut 
into four rings of approximately 3 mm in length, mounted 
on stainless teel hooks, placed in organ chambers filled 
with Krebs-Henseleit solution (37 ° C, gassed with 95% 02 
and 5% CO2), and connected to force transducers (Rad- 
noti model TR 001, Monrovia, Calif.). The rings were 
allowed to equilibrate at a passive tension of 1 gin. After 
60 minutes of equilibration, the optimal length-tension 
relationship was determined by progressively stretching 
the rings and recording the maximal contractile response 
to a 30 mmol/L dose of potassium chloride. The rings were 
incubated with indomethacin 10 txmol/L and precon- 
tracted with U46619 10 nmol/L (Upjohn Co., Kalamazoo, 
Mich.), a thromboxane A2 mimetic agent, and dose- 
relaxation responses to acetylcholine, A23187, and acidi- 
fied NaNO a were determined as previously describedJ 2 
Drug concentrations are expressed as final concentrations 
in the organ chambers. 
Plasma creatine kinase activity. Blood samples for 
the measurement of creatine kinase activity were with- 
drawn from the femoral artery and the plasma sepa- 
rated by centrifugation and analyzed spectrophoto- 
metrically as described previously. 2° Creatine kinase 
activity was expressed in international units per micro- 
gram of protein. 
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Table II. Myocardial temperature and delivery volume of BCP at each infusion 
Myocardial temperature U C) BCP volume (ml) 
Time VEH SPM-L SPM-H VEH SPM-L SPM-H 
I schemia  36.4 _+ 0.1 36.3 -- 0.4 36.3 -+ 0.2 - -  - -  - -  
Induct ion  12.8 -4- 1.0" 13.5 + 0.5* 14.0 +_ 1.2" 584 _+ 39 488 _+ 28 513 -- 52 
20 min  14.1 + 0.8* 14.0 _+ 0.5* 13.4 -- 0.7* 189 _+ 15" 218 +- 16 '  213 _+ 25* 
40 rain 12.8 _+ 0.8* 14.9 -+ 0.6* 13.6 -+ 0.8* 209 _+ 22* 179 +- 19" 209 _+ 28* 
60 rnin 33.6 _+ 0.6 29.4 -+ 1.4 32.7 _+ 0.5 413 _+ 45 368 - 25 468 +_ 41 
*p < 0.05 versus unstarred time periods within each group. 
Cardiac myeloperoxidase (MPO) activity. T ssue sam- 
ples weighing approximately 0.2 gm were taken from the 
anterior and posterior walls of the left ventricle for 
measurement of MPO activity as an assessment of neu- 
trophil accumulation i myocardium. 21The activity of 
MPO was measured spectrophotometrieally nd ex- 
pressed as units per 100 mg tissue. One unit of MPO 
activity was defined as the quantity of enzyme degrading 
1/xmol of peroxide per minute at 25 ° C. 
Statistical analysis. All data were analyzed with the 
Statistical Analysis System program (PC-SAS, SAS Insti- 
tute, Cary, N.C.). Time-related ifferences and group- 
time interactions of ESPVR and PRSW parameters 
and creatine kinase activity were analyzed by two-way 
analysis of variance for repeated measures adjusted for 
baseline values. BCP variables, isolated coronary ring 
data, and MPO data were compared among the three 
groups by one-way analysis of variance. A value of p < 
0.05 was considered statistically significant. All data were 
presented as means plus or minus standard error of the 
mean. 
Results 
Three dogs in the VEH group could not be 
weaned off bypass because of severe left ventricular 
failure during reperfusion. One dog from each 
SPM-5185 group was excluded because of persistent 
arrhythmias. Eighteen dogs (6 from each group) 
were entered into the final data analysis. 
Myocardial temperature and elivery of BCP 
solution (Table II). Myocardial temperatures 
achieved during both normothermic schemia and 
cardioplegic infusion were comparable among 
groups. The volumes of BCP solution delivered in 
each group were comparable at each infusion inter- 
val. Significantly greater volumes of BCP solution 
were delivered during induction and 60 minutes of 
arrest compared with those delivered uring the 20- 
and 40-minute intermittent infusions. 
ESPVR. All three groups were comparable at the 
preischemic period in slope (Ees), volume-axis nter- 
cept (Vo), and the midrange volume-axis intercept 
(VMID) of the ESPVR (Fig. 2). In the VEH group, 
postischemic Ees was significantly decreased by 48% 
from its preischemic value. In the SPM-L group, 
there was a 30% decrease in Ees from baseline levels 
(p < 0.05), but postischemic Eos tended to be 
greater than that in the VEH group. In contrast, 
postischemic Ees was not significantly different from 
its preischemic value in the SPM-H group and was 
significantly greater than that in the VEH group. 
Postischemic Vo values tended to be less than the 
corresponding preischemic values in all groups, but 
there were no statistically significant differences 
between preischemic and postischemic values. 
These changes in V o are consistent with a pivotal 
shift in the ESPVR. Although postischemic VMm 
significantly increased compared with the preisch- 
emic value in the VEH group, there were no statis- 
tically significant differences in postischemic VMID 
among the three groups because of counterbalanc- 
ing changes in Ees and Vo. 
PRSW. The PRSW as an index of integrated 
systolic and diastolic left ventricular performance 
agreed with the results observed with ESPVR (Ta- 
ble III). The VEH group showed depressed post- 
ischemic performance, manifested as a 26.5% de- 
crease in the slope of PRSW from baseline. In 
contrast, the postischemic slope of PRSW in the 
SPM-L group demonstrated only a slight depression 
(6.6%) compared with baseline values. Interestingly, 
the SPM-H group showed increased slope of PRSW 
after reperfusion compared with the baseline value. 
Chamber stiffness. Preischemic chamber stiffness 
was comparable among groups (VEH, 0.035 + 
0.007; SPM-L, 0.032 _+ 0.010; SPM-H, 0.013 -+ 
0.009). Postischemic end-diastolic chamber stiffness 
tended to be higher than baseline values in all 
groups. However, chamber stiffness was not signifi- 
cantly different between baseline and postischemic 
values in any group (VEH, 0.046 +_ 0.004; SPM-L, 
0.054 _ 0.006; SPM-H, 0.028 + 0.015). There were" 
no differences in baseline or postischemic chamber 
stiffness values among groups. 
Plasma creatine kinase activity. There were no 
significant differences among groups in plasma cre- 
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Fig. 2. Variables describing analysis of y tolic function by
ESPVR in preischemic (Pre) and postishemic (Post) period. 
Toppanel, Slope of ESPVR (E~s). Middle panel, Volume axis 
intercept of ESPVR (Vo). Bottom panel, Volume axis value 
(VMID) at Pcs within physiologic range (80 to 100 mm Hg), 
describing position f ESPVR. Asterisk, p < 0.05 versus 
preischemic period; plus sign, p < 0.05 versus VEH. 
atine kinase activities at baseline (Table IV). None 
of the three groups showed an elevation of creatine 
kinase activities after 30 minutes of normothcrmic 
ischemia nd 60 minutes of BCP arrest. After blood 
reperfusion, however, plasma creatine kinase activ- 
ities were increased in all groups but without signif- 
icant group differences. 
Cardiac MPO activity. There were no differences 
in MPO activities between anterior and posterior 
walls in each group, so the samples were pooled. 
MPO activities in the SPM-H group were signifi- 
_ 
,_, 44  





VEH SPM-L SPM-H 
Fig. 3. MPO activity, an index of neutrophil accumula- 
tion in postischemic myocardial tissue samples from ach 
group. Asterisk, p < 0.05 versus VEH. 
cantly less than those in the VEH group (Fig. 3). 
There were no significant differences in MPO activ- 
ities between the SPM-L and SPM-H groups. These 
data indicate that high concentrations of SPM-5185 
treatment reduced neutrophil accumulation in the 
myocardium subjected to ischemia nd reperfusion 
compared with no SPM-5185 treatment. 
In vitro coronary ring data. Relaxation data from 
isolated left anterior descending and circumflex 
coronary arterial rings were statistically similar and 
were pooled (Fig. 4). The endothelium-dependent 
receptor-mediated vasodilator acetylcholine caused 
relaxations in a concentration-dependent manner in 
all three groups. However, differences in the mag- 
nitude of response were observed among groups. 
The concentration response curves to acetylcholine 
in the VEH and SPM-L groups were markedly 
shifted to the right with a reduction in the maximum 
relaxation compared with that in the SPM-H group. 
In addition, the maximum responses to acetylcho- 
line in the SPM-H group were significantly greater 
than those in the VEH group. The endothelium- 
dependent onreceptor-mediated vasodilator A23187 
also caused concentration-dependent relaxation in all 
three groups. Responses to the second concentration 
of A23187 (0.005/~mol/L) in the SPM-H group were 
significantly greater than those in the VEH and 
SPM-L groups. In addition, responses to the fourth 
concentration of A23187 (0.0125 /~mol/L) in the 
SPM-L and SPM-H groups were significantly greater 
than those in the VEH group. However, responses to 
other concentrations of A23187 were comparable 
among the groups, with complete relaxations at higher 
concentrations of A23187 in all three groups. 
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Table IlL Summary of variables describing analysis of systolic performance by the PRSW index, which 
integrates systolic function and diastolic characteristics, and diastolic chamber stiffness by [3 coefficient at 
preischemic and postischemic periods 
Msw (ram Hg. rnl/ml) Vsw, o (ml) J3 Coefficient 
Group Pre Post Pre post Pre Post 
VEH 65.02 _+ 6.24 47.84 + 6.30"t 16.33 -+ 4.23 18.65 + 3.79 0.035 + 0.007 0.047 _+ 0.004 
SPM-L 71.18 + 11.18 66.50 +_ 6.21 13.96 -+ 3.62 13.81 _+ 1.87 0.032 _+ 0.011 0.054 _+ 0.006 
SPM-H 50.51 + 4.76 67.57 -+ 5.80 17.31 + 2.88 15.35 -+ 3.30 0.013 +_ 0.009 0.028 + 0.015 
Msm Slope of PRSW relation; Vsw,,o volume axis intercept of the PRSW relation; Pre, preischemic period; Post, postischemic period. 
*p < 0.05 versus preischemic period. 
tp < 0.05 versus SPM-H. 
Responses to the endothelium-independent vaso- 
dilator sodium nitrite showed no impairment and no 
differences among the groups with any concentra- 
tion of sodium nitrite. These data indicate that 
high-dose SPM-5185 protects endothelial function 
from ischemia and reperfusion damage and that 
endothelium-dependent nonreceptor-mediated r - 
sponses and smooth muscle function remain almost 
intact after ischemia nd reperfusion. 
Relation between recovery of Ees and responses to 
acetylcholine. To evaluate the relationship between 
the extent of left ventricular functional recovery and 
endothelial function, the percent recovery of post- 
ischemic Ees and maximum relaxation to acetylcho- 
line from each dog were plotted. The recovery of Ees 
and responses to acetylcholine were only modestly 
correlated (r = 0.36,p = 0.46). The equation for this 
relationship isy = 0.50x + 22.1, where y = percent 
functional recovery and x = percent maximum re- 
laxation. There was only a mild tendency for the 
recovery of ventricular performance and endothelial 
function to be correlated. 
Discussion 
The effect of chemical cardioplegia on endothelial 
cell structure and function is controversial. Earlier 
studies have shown that crystalloid cardioplegia nd 
BCP cause endothelial damage, 22-25 whereas other 
studies found that endothelial damage was pre- 
vented by the use of BCP. 22' 25 Our recent study 
demonstrated that functional and morphologic 
damage to the coronary vascular endothelium in 
injured hearts was manifest not during chemical 
cardioplegia, but rather during subsequent blood 
reperfusion. 12The results from the present study 
show that an organic NO donor compound, SPM- 
5185, used as an adjunctive agent o BCP, prevented 
postischemic endothelial injury and attenuated 
postischemic left ventricular dysfunction in a dose- 
Table IV. Plasma creatine kinase activity 
(international units per microgram protein) during 
the time course of the experiment 
Group Preischemia Ischemia BCP Reperfusion 
VEH 10.43 _+ 1.91 11.85 _+ 1.82 14.85 -+ 2.03 24.11 +_ 3.95 
SPM-L 8.93 _+ 1.83 9.69 -+ 1.02 12.55 -+ 0.37 29.62 + 6.33 
SPM-H 7.80_+ 1.21 8.75 -+ 1.17 12.65 -+ 1.95 16.83 -+ 1.93 
Ischemia, After 30 minutes of normothermic ischemia; BCP, after last (60 
minutes) delivery of blood cardioplegia; reperfusion, after a total of 60 
minutes of reperfusion after removal of aortic crossclamp. 
dependent manner in dogs subjected to normo- 
thermic global ischemia, cardioplegic arrest, and 
reperfusion. Whereas the VEH and SPM-L groups 
demonstrated 52% and 30% depressions of post- 
ischemic systolic performance assessed by ESPVR, 
respectively, the SPM-H group reversed this post- 
ischemic ontractile dysfunction. In addition, endo- 
thelium-dependent relaxations to acetylcholine were 
impaired in the isolated coronary arteries from the 
VEH and SPM-L groups, with maximum relaxations 
being 78% and 90%, respectively. On the other 
hand, postischemic oronary arteries from the 
SPM-H group showed significantly better elaxation 
to acetylcholine (maximum relaxation 108%). The 
recovery of systolic function assessed by ESPVR and 
the maximum relaxation responses to acetylcholine 
were only moderately correlated. A reduction in 
neutrophil accumulation i the SPM-H group sug- 
gests a neutrophil mechanism of cardioprotection. 
Although SPM-5185 is a vasodilator, there was no 
increase in cardioplegia volume delivery to contrib-. 
ute to better myocardial preservation. 
One of the major findings in the present study is 
that neutrophil accumulation in the myocardium 
(assessed by MPO activity) was reduced in the 
SPM-H group, which suggests an antineutrophil 
mechanism for SPM-5185. Neutrophil activation 
and adherence to the coronary vascular endothe- 
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Fig. 4. Concentration response curves to acetylcholine, the calcium ionophore A23187, and 
acidified sodium nitrite in coronary arterial rings from each group. Values are expressed as 
percent change in tension from precontraction with thromboxane A 2 an logueU46619. 
Asterisk, p < 0.05 versus VEH and SPM-L; plus sign, p < 0.05 versus VEH. 
lium are thought o be key factors in postischemic 
injury in that activated neutrophils generate oxygen- 
derived free radical species, 26 release proteolytic 
enzymes, and aggregate and embolize in the micro- 
vasculature. In fact, adherence ofneutrophils to he 
coronary vascular endothelium is thought o be a 
prerequisite for neutrophil-induced inflammatory 
damage. 27SPM-5185, as an organic donor of NO, 
may inhibit the aforementioned sequence of events 
in the cascade of neutrophil-induced damage. NO 
inhibits adherence of neutrophils to the coronary 
endothelium,28, 29 whereas inhibition of NO produc- 
tion by L-nitro-monomethyl arginine 7 or reperfusion 
injury 3° increases neutrophil adherence. Further- 
more, NO directly reduces oxyradical generation by 
neutrophils 31and may inactivate superoxide anions 
by biradical quenching. 32 
The role of NO in the setting of myocardial isch- 
emic-reperfusion injury is intensely controversial, with 
some studies (including the present study) attributing 
a beneficial effect 4' 28,33-35 and others howing a dele- 
terious effect. 36-39 The study of Matheis and associ- 
ates, 39 for example, showed that inhibition of endoge- 
nous NO improved posthypoxic functional recovery, 
thereby indirectly supporting a deleterious role for 
NO. The mechanisms underlying these purported el- 
eterious effects include the breakdown of NO to 
peroxynitrite and hydroxyl radicals. 37'4° However, 
other studies have not shown NO to be cytotoxic, even 
in the presence of peroxynitrite derivatives. 41 The 
controversy may be related to dose-dependent ffects 
of NO or differing roles of NO in ischemic-reperfused 
myocardium as opposed to hypoxic myocardittm or
shock states. Because NO synthase and hence the 
production of NO are dependent on the presence of 
oxygen, the level of substrate oxygen in the various 
models may be a factor that determines when (for 
example, ischemia w th scant oxygen supply and reper- 
fusion with adequate oxygen supply) and how much 
NO is produced. In addition, recent evidence suggests 
that peroxynitrite is "recycled" to nitrosothiols or NO 
itself in in vivo environments, instead of producing 
hydroxyl and nitrogen dioxideradicals. 42 The present 
study adds to the body of data that support a beneficial 
effect of NO, even at relatively high concentrations 
achieved by an exogenous NO donor. 
The endothelium is a pivotal interface between the 
vascular space and myocardial parenchyma because it 
is the site of initiation of neutrophil activation, which 
touches off emigration into the interstitium and sub- 
sequent neutrophil-mediated d mage to the myocyte. 
This role of the endothelium would link endothelial 
dysfunction, eutrophil activation, and contractile dys- 
function as related events. Our data showing endothe- 
lial injury, neutrophil accumulation, and postischemic 
contractile dysfunction are consistent with this se- 
quence of events. Indeed, we found that the degree of 
endothelial injury and postischemic contractile dys- 
function were moderately correlated, but with a defi- 
nite trend. An improved correlation may be obtained if 
endothelial injury across the microvasculature and the 
macrovasculature is correlated inasmuch as small ves- 
sels and capillaries may be more sensitive to endothe- 
lial injury that larger conductance v ssels. In addition, 
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a better correlation may be derived if coronary venous 
endothelial dysfunction is correlated with contractile 
dysfunction because neutrophils adhere to and emi- 
grate predominantly through the coronary veins. 43 
In summary, the present study demonstrates that 
the addition of the NO donor SPM-5185 in BCP 
preserves postischemic left ventricular function and 
coronary endothelial function in canine hearts sub- 
jected to antecedent normothermic global ischemia 
and cardioplegic arrest and reperfusion. The degree of 
protection was dose dependent inasmuch as SPM- 
5185 at a concentration of 1/xmol/L in BCP showed 
partial protection whereas 10 /zmol/L demonstrated 
full recovery after ischemia. Because these cytoprotec- 
tive effects of SPM-5185 were associated with reduc- 
tion of neutrophil accumulation i the myocardium, 
the mechanism of this protection appears to be related 
to inhibition of neutrophils. However, further studies 
are necessary to determine the precise mechanisms of
cytoprotection bySPM-5185 in cardioplegic arrest and 
reperfusion. It would also be interesting to investigate 
whether normothermic nduction cardioplegia would 
enhance the cardioprotection of an NO donor by 
accelerating biochemical interactions between NO and 
neutrophils. In addition, it is not clear from the present 
study whether SPM-5185 exerts its protection during 
the period of cardioplegic ischemia or during the 
subsequent period of reperfusion. Finally, it would be 
interesting to determine whether NO donor therapy in 
the absence of cardioplegic ischemia would avoid 
postischemic injury, which would further confirm a 
role for NO donors in the attenuation of reperfusion 
injury. 
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